February 26, 2026
Speakers: Michael G. King, Ron Baker , Federica Frati, PhD, Gabi Hanna, MD, Michael Stocum
Get the inside track on oncology investment and partnering trends following JPM Week. Our panelists will highlight the most important oncology updates coming out of San Francisco and share what to expect heading into BIO Partnering for Oncology (May 29–June 2, 2026, in Chicago),…

March 17, 2026
Speakers: Tamy Dalal, Jeff Vallerga, Jose Arellano, Clark Chandler, Brandon Clough, Lori Cotsack, Matt Curry , Sarah Glazier, Greg Hassan, Steve Joseph, Carrie Kleinle, Ric Kunnert, Gaby Levey, Alina Mencias, Tina Nuthulaganti, Dalton Speelman , Jim Tilton, Dave Tucker
BIO Savings Week connects life science companies with the lab and business solutions available through their BIO or state life science association membership. Across three days, you will hear directly from BIO Business Solutions' preferred providers about programs tailored to…

March 26, 2026
Speakers: Ryan Lowry, Sydney Williams, Nicholas Zuccaro
Join Sydney Williams, BIO Senior Manager, Exhibit Sales & Systems, along with members of the BIO Partnering team, for a webinar to walk exhibitors through the tools needed to plan for the 2026 BIO International Convention. Exhibitors will be provided with the resources…


Every year, JPM Healthcare Week sets the pace for biotech deal-making. But the skills and insights you gain from preparing for high stakes partnering meetings are valuable long after January. In this webinar, a panel of investors and biotech executives will share what makes a pitch stand out, common pitfalls to avoid and practical guidance you can use not just at JPM Week, but at events like the BIO Investment & Growth Summit (March 2-3, Miami Beach) and other partnering opportunities throughout the year. Learn how to register for BIO events at this link.
This webinar features:
- Strategies and tips for making the most of your time during JPM Week
- Methods for improving your partnering meetings
- How to access the BIO and Novateur Ventures JPM Week Events Guide mobile app
- What to expect at the 2026 BIO Investment and Growth Summit
- Live Q&A with the speakers

In September 2025, the U.S. FDA launched a major enforcement campaign targeting direct-to-consumer (DTC) pharmaceutical advertising that misleads patients or downplays risks. Following a September 2025 presidential directive, the agency announced hundreds of enforcement actions—including over 100 cease-and-desist letters—signaling a zero-tolerance stance toward unbalanced or deceptive ads. While most of the letters focused on DTC content, FDA also sent letters for health care provider (HCP) promotion. The message: Government scrutiny and enforcement will significantly increase for biopharma as well as medical device promotion. This webinar includes regulatory compliance and drug advertising compliance experts who dissect the FDA’s mindset and ways to proactively mitigate concerns.
In this webinar, panelists:
– Drill down into FDA’s renewed enforcement areas
– Dissect the implications of increased enforcement on the industry
– Identify specific cases that are clear examples for company concern
– Isolate the key principles for avoiding violations and demonstrating good faith

Wrap up the week with an executive overview of BIO Business Solutions and a deep dive with our flagship partner, Avantor. Learn how the program delivers ongoing value and discover exclusive offers and procurement strategies available to BIO members.
Agenda Overview:
- BIO Business Solutions Overview by BIO Vice President of Business Development, Jeff Vallerga
- Avantor – Learn how to drive purchasing efficiency and lab performance with one of the life science industry's leading suppliers. From everyday consumables to capital equipment, discover how member companies leverage Avantor’s flagship program for exclusive pricing, custom sourcing support, and supply chain optimization.
- Q&A
- Closing Remarks & Next Steps
BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.

Join Thermo Fisher Scientific for an exclusive webinar introducing a transformative approach to biologics development and clinical scale-up. Their "Path to IND for Biologics" method accelerates the journey from DNA to IND/IMPD submission and first-in-human clinical trials in as few as 9 months. Dr. Elena Gontarz, a leading expert in the biologics industry, will guide you through this innovative process, leveraging AI/ML, transposase technology, and integrated solutions during the session: "Path to IND for Biologics: From DNA to First-in-Human in 9 Months." Following the presentation, Dr. Gontarz will answer audience questions and discuss how these novel strategies can streamline the development of complex biologics, such as Fc-fusion proteins and bispecific antibodies, driving them swiftly from development to commercialization.
Get a sneak peek on this novel platform
Terms and Conditions: Titer levels provided are estimates based on third party results and may vary depending on molecule type or other factors. Timeline from DNA to drug product and start of clinical trials for all path to IND for biologics options may vary depending on molecule type or other factors and are estimates to be finalized after third party cell line development dates are available and confirmed. 9-month timeline will incur additional risk.
Learn more about Dr. Elena Gontarz's expertise and background:

View this webinar for an in-depth exploration of today's complex global market landscape. This panel will address the challenges of launching new therapies in multiple countries, focusing on early decision points for risk mitigation and maximizing supply chain resiliency. Discover how Cencora's global capabilities and flexible solutions can strengthen supply chain resilience amidst evolving challenges.
Moderator: Sandra Anderson, Senior Vice President Commercialization, Cencora
Panelists:
- Glenn Pauly, Chief Commercial Officer, Alzheon
- Graham Goodrich, Chief Commercial Officer, Apnimed
- Leigh Shultz, PhD, Associate Vice President & International Head of Trade Channel Strategy & Enablement, Merck & Co.
- Kevin McDermott, Vice President International Commercialization, Cencora
- Tom Doyle, Head of U.S. Commercial Solutions, Cencora
More than $4B of deals between biopharma companies and AI specialists were announced last year. Similar to the massive quality leap from GPT-2 to GPT-4 and the record-breaking consumer adoption rates of AI tools, that same exponential progress and uptake is coming to biotech AI. 2024 may bring the first one-trillion-parameter protein language model. Companies are already using AI to program, as opposed to discover, antibodies. This level of opportunity and change brings with it urgency—— companies need to rethink from the ground up how their R&D should work to compete in a new era defined by the intersection of biology, data, and AI.
In this webinar, learn how companies are updating their approach to R&D, with a focus on:
- AI-Ready Data: Improving generation of high-quality biomedical data to support AI model building and model tuning
- AI-Enabled Scientists: Integrating the right models directly into scientists’ workflows for everyday use
- Scalability: Making performance, speed, privacy, and cost tradeoffs for deployment of AI, and connecting the wet and dry labs

With the majority of biological studies conducted in academic settings but nearly all innovative new drug clinical trials sponsored by industry, improving translational research success rates for commercialization is critical to bringing new treatments to patients. Surveys of academic tech transfer offices and the biopharma industry executives working on such alliances cite as obstacles two highly controllable factors: disagreement about alliance performance metrics and misalignment of deal terms priorities. This panel discusses best practices for removing such obstacles to accelerate more promising ideas into clinical development for patients.
BIO's updated 2023 report, "U.S. Biotechnology Translational Research: Partnership Models, Management Principles, and Best Practices," is available for download at the link below. The webinar also summarizes major findings from that BIO report as context for the panel discussion and audience Q&A.

The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle.
Moderator:
– Anne-Virginie Eggimann, Tessera
Opening Remarks:
– Cartier Esham, Senior Advisor, Biotechnology Innovation Organization (BIO)
Speaker:
– Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals

The 2026 BIO International Convention is Driven by Purpose—united by our shared mission to push boundaries, solve the impossible and achieve better outcomes for patients, public health, and the world. In that same spirit, BIO Partnering™ is designed to help you turn that purpose into action by connecting with the right partners, collaborators and investors who can help bring your innovations to life.
Join Mackensie Vernetti, BIO’s Vice President of Partnering, for a practical, purpose-driven walkthrough of how to use the BIO Partnering system effectively. This webinar will show you how to:
- Make use of the system’s newest features
- Create a compelling partnering profile that highlights your mission and capabilities
- Identify and evaluate potential partners who align with your goals
- Send targeted, effective meeting requests that lead to meaningful connections
- Manage your schedule and maximize your time at BIO 2026
BIO 2026 is where we return to our essential “why.” This session will help ensure you arrive ready to partner with purpose—and make every meeting count.

Join Sydney Williams, BIO Senior Manager, Exhibit Sales & Systems, along with members of the BIO Partnering team, for a webinar to walk exhibitors through the tools needed to plan for the 2026 BIO International Convention.
Exhibitors will be provided with the resources to make an impactful presence in San Diego.
This webinar will cover the following topics:
- Exhibitor resource center
- Exhibitor tools and resources
- Exhibitor Booth Partnering
- Tips to maximize your event experience in San Diego

BIO Savings Week connects life science companies with the lab and business solutions available through their BIO or state life science association membership. Across three days, you will hear directly from BIO Business Solutions' preferred providers about programs tailored to different roles—from founders and operations leaders to lab managers and admins.
All sessions are open to BIO and state affiliate members and include Q&A and life science-focused strategies.
BIO Business Solutions® is the largest cost-savings program for the life sciences industry, leveraging the collective buying power of thousands of member companies to deliver exclusive pricing on lab supplies, insurance, office essentials, and more, all at no additional cost to members.
Day 1 - Foundational Tools
Tuesday, March 17, 2026, 2:00–3:00 p.m. (Eastern Time)
A focused look at the foundational tools early-stage life science companies need to launch and scale. Learn how membership benefits support HR, finance, compliance, and leadership decisions during the earliest stages.
Featured Partners:
- ADP HR
- Greg Hassan, Director of Franchise & Affiliations
- ADP Tax Credits
- Jose Arellano, Senior Director of Channel Strategy
- Brex
- Gaby Levey, Startup Partnerships Manager
- BiotechExec
- Steve Joseph, Executive Vice President, Strategic Partnerships
- PSC Biotech
- Brandon Clough, Managing Director of Operations – Central Region
- PSC Software
- Clark Chandler, Manager, Sales Development
Day 2 - Core Business Operations Support
Wednesday, March 18, 2026, 2:00–3:00 p.m. (Eastern Time)
An overview of the savings and benefits supporting core business operations, from travel and logistics to office purchasing and secure data management.
Featured Partners:
- Corporate Traveler
- Matt Curry, Principal Account Executive
- Dave Tucker, Principal Account Executive
- ODP Business Solutions
- Sarah Glazier, Senior Contract Sales Manager
- UPS Healthcare
- Alina Mencias, Americas Product Marketing & Go-to-Market Strategy
Day 3 - Lab Solutions & Products
Thursday, March 19, 2:00–3:00 p.m. (Eastern Time)
Designed for lab managers and R&D leaders, this session explores the lab solutions and benefits that support research environments—from equipment and lab supply procurement to safety and compliance.
Featured Partners:
- Airgas Healthcare
- Dalton Speelman, National Account Manager, Airgas Life Sciences
- American Laboratory Trading
- Carrie Kleinle, Director, Product Marketing & Partner Engagement
- Clean Harbors
- Lori Cotsack, Corporate Account Manager
- SU Group
- Ric Kunnert, Regional Sales Manager
- UniFirst
- Jim Tilton, National Sales Manager
- VWR, part of Avantor
- Tina Nuthulaganti, Director, Strategic Alliances

Get the inside track on oncology investment and partnering trends following JPM Week. Our panelists will highlight the most important oncology updates coming out of San Francisco and share what to expect heading into BIO Partnering for Oncology (May 29–June 2, 2026, in Chicago), BIO’s newest B2B event focused on accelerating cancer-therapeutics innovation and deal-making.

Get ready to take your business development strategy from the boardroom to the beach at the BIO Investment & Growth Summit, happening March 2–3, 2026, in sunny Miami Beach!
Before you pack your sunglasses, join this lively walkthrough of the BIO Partnering™ system—your essential tool for connecting with investors, innovators, and dealmakers who can take your company to the next level.
In this session, you’ll learn how to:
- Craft a standout partnering profile that catches attention
- Search for and identify high-value partners and investors
- Send targeted meeting requests that lead to real opportunities
- Manage your schedule so you can focus on making deals and maybe catch a few rays)
- Don’t miss this chance to ride the wave of opportunity and arrive in Miami ready to make the most of every meeting.

Every year, JPM Healthcare Week sets the pace for biotech deal-making. But the skills and insights you gain from preparing for high stakes partnering meetings are valuable long after January. In this webinar, a panel of investors and biotech executives will share what makes a pitch stand out, common pitfalls to avoid and practical guidance you can use not just at JPM Week, but at events like the BIO Investment & Growth Summit (March 2-3, Miami Beach) and other partnering opportunities throughout the year. Learn how to register for BIO events at this link.
This webinar features:
- Strategies and tips for making the most of your time during JPM Week
- Methods for improving your partnering meetings
- How to access the BIO and Novateur Ventures JPM Week Events Guide mobile app
- What to expect at the 2026 BIO Investment and Growth Summit
- Live Q&A with the speakers

In September 2025, the U.S. FDA launched a major enforcement campaign targeting direct-to-consumer (DTC) pharmaceutical advertising that misleads patients or downplays risks. Following a September 2025 presidential directive, the agency announced hundreds of enforcement actions—including over 100 cease-and-desist letters—signaling a zero-tolerance stance toward unbalanced or deceptive ads. While most of the letters focused on DTC content, FDA also sent letters for health care provider (HCP) promotion. The message: Government scrutiny and enforcement will significantly increase for biopharma as well as medical device promotion. This webinar includes regulatory compliance and drug advertising compliance experts who dissect the FDA’s mindset and ways to proactively mitigate concerns.
In this webinar, panelists:
– Drill down into FDA’s renewed enforcement areas
– Dissect the implications of increased enforcement on the industry
– Identify specific cases that are clear examples for company concern
– Isolate the key principles for avoiding violations and demonstrating good faith

BIO is back at the San Francisco Marriott Marquis for JPM Week 2026—now powered by the new BIO Partnering™ system with major upgrades to help you connect more efficiently.
View this webinar to see how the overhauled self-scheduling tools and exciting new features—like AI Assist for generating tailored meeting request messages—can help you source new partnerships and manage your JPM Week meetings with ease. Learn about BIO’s onsite meeting space in San Francisco, tips and tricks for maximizing the system and how to schedule across various location options. Plus, find out how to stay in-the-know on networking events and other opportunities throughout JPM Week.
This webinar covers:
- Preview of BIO’s onsite meeting space in San Francisco
- Partnering best practices & how to schedule your meetings
- Live demo of the new BIO Partnering system & advanced features
- Intro to BIO and Novateur Ventures’ JPM Week Events Guide mobile app
- Q&A with the host
Learn more and register at https://bpjw.bio.org/

Rising service agreement costs and shrinking support from original equipment manufacturers (OEMs) have created a growing challenge for life science organizations. Many labs are stuck juggling multiple contracts, vendors, and renewal cycles — losing both time and money along the way.
This webinar explores an alternative approach: centralizing lab equipment service events under one provider. You’ll hear from experts at SU Group, a company with decades of actuarial data on lab equipment performance, and from Joe Dragavon, Director Core Facilities and Shared Instrumentation & Research and Innovation Office Director, Advanced Light Microscopy Core BioFrontiers Institute, who successfully implemented this model and realized both cost savings and efficiency gains.
Attendees will walk away with:
- A clear understanding of the challenges with today’s service agreement landscape
- An introduction to a centralized, data-driven model for managing equipment service
- A real-world example of how this model works in practice and the benefits achieved
- Practical considerations for evaluating whether this approach is right for your organization














